By physician referral or invitation only

MCC18613: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

To assess the antitumor activity of nab-paclitaxel combined with gemcitabine in patients with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma using and progression-free survival.

Age & Gender

3 years ~ 30 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Patrick Thompson
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue))
Child and Teen Health

IRB Number

17-0804

ClinicalTrials.gov

NCT02945800

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.